80 related articles for article (PubMed ID: 24154839)
1. Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.
Cercek A; D'Angelica M; Power D; Capanu M; Gewirtz A; Patel D; Allen P; Fong Y; DeMatteo RP; Jarnagin WR; Kemeny NE
Ann Surg Oncol; 2014 Feb; 21(2):479-86. PubMed ID: 24154839
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer.
Kemeny NE; Jarnagin WR; Capanu M; Fong Y; Gewirtz AN; Dematteo RP; D'Angelica MI
J Clin Oncol; 2011 Mar; 29(7):884-9. PubMed ID: 21189384
[TBL] [Abstract][Full Text] [Related]
3. Current Practices in Hepatic Artery Infusion (HAI) Chemotherapy: An International Survey of the HAI Consortium Research Network.
Judge SJ; Ghalambor T; Cavnar MJ; Lidsky ME; Merkow RP; Cho M; Dominguez-Rosado I; Karanicolas PJ; Mayo SC; Rocha FG; Fields RC; Patel RA; Kennecke HF; Koerkamp BG; Yopp AC; Petrowsky H; Mahalingam D; Kemeny N; D'Angelica M; Gholami S
Ann Surg Oncol; 2023 Nov; 30(12):7362-7370. PubMed ID: 37702903
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.
Gigante E; Bouattour M; Bedoya JU; Regnault H; Ziol M; Assenat E; Paradis V; Calderaro J; Ganne-Carrié N; Bouhier-Leporrier K; Amaddeo G; Nault JC
United European Gastroenterol J; 2024 May; 12(4):429-439. PubMed ID: 38059651
[TBL] [Abstract][Full Text] [Related]
5. Robotic Versus Open Hepatic Arterial Infusion Pump Placement for Unresectable Intrahepatic Cholangiocarcinoma.
Ten Haaft BHEA; Franssen S; van Dorst RWJJ; Rousian M; Pilz da Cunha G; de Wilde RF; Erdmann JI; Groot Koerkamp B; Hagendoorn J; Swijnenburg RJ
Ann Surg Oncol; 2024 Jun; 31(6):4022-4029. PubMed ID: 38498089
[TBL] [Abstract][Full Text] [Related]
6. Phase I Safety and Feasibility Pilot of Hepatic Artery Infusion Chemotherapy in a Rural Catchment Area Using The Codman Vascular Catheter with The Medtronic SynchroMed II Pump for Intrahepatic Cancers.
McDonald HG; Zaki OA; Wright MJ; Jayswal R; Weiss H; Nair RT; Ganesh H; Ellis S; Kolesar JM; Moss J; Barry-Hundeyin M; Pandalai PK; Kim J; Patel RA; Cavnar MJ
Ann Surg Oncol; 2024 Feb; 31(2):1252-1263. PubMed ID: 38006531
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma.
Franssen S; Soares KC; Jolissaint JS; Tsilimigras DI; Buettner S; Alexandrescu S; Marques H; Lamelas J; Aldrighetti L; Gamblin TC; Maithel SK; Pulitano C; Margonis GA; Weiss MJ; Bauer TW; Shen F; Poultsides GA; Marsh JW; Cercek A; Kemeny N; Kingham TP; D'Angelica M; Pawlik TM; Jarnagin WR; Koerkamp BG
JAMA Surg; 2022 Jul; 157(7):590-596. PubMed ID: 35544131
[TBL] [Abstract][Full Text] [Related]
8. Hepatic artery infusion chemotherapy with systemic capecitabine and camrelizumab for treating unresectable hilar cholangiocarcinoma: An initial investigation of efficacy and safety.
Li L; Liu S; Wang Q; Wang Y; Yu G
J Cancer Res Ther; 2024 Apr; 20(2):578-583. PubMed ID: 38687927
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of the efficacy and safety of hepatic arterial infusion chemotherapy for unresectable hepatitis B-related intrahepatic cholangiocarcinoma].
He MR; Zheng ZK; Wu TQ; Chen MS; Zhou ZG
Zhonghua Wai Ke Za Zhi; 2024 Apr; 62(4):309-315. PubMed ID: 38432672
[No Abstract] [Full Text] [Related]
10. Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
Jang YJ; Kim EJ; Kim HD; Kim KP; Ryu MH; Park SR; Choi WM; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY; Yoo C
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7547-7555. PubMed ID: 36971796
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.
Subbiah IM; Subbiah V; Tsimberidou AM; Naing A; Kaseb AO; Javle M; Fu S; Hong DS; Piha-Paul S; Wheler JJ; Hess KR; Janku F; Falchook GS; Wolff RA; Kurzrock R
Oncotarget; 2013 Jan; 4(1):156-65. PubMed ID: 23391555
[TBL] [Abstract][Full Text] [Related]
12. Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.
Kobayashi S; Fukushima T; Ueno M; Chuma M; Numata K; Tsuruya K; Arase Y; Hirose S; Kagawa T; Hattori N; Watanabe T; Matsunaga K; Uojima H; Hidaka H; Kusano C; Morimoto M; Maeda S
Liver Int; 2024 Jun; 44(6):1343-1350. PubMed ID: 38436529
[TBL] [Abstract][Full Text] [Related]
13. Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-Level Evidence.
Kuemmerli C; Hess V; Dutkowski P; Sinz S; Kessler U; Hess GF; Billeter AT; Müller-Stich BP; Kollmar O; Müller PC
Pharmacology; 2024; 109(2):86-97. PubMed ID: 38368862
[TBL] [Abstract][Full Text] [Related]
14. Safety and feasibility of establishing an adjuvant hepatic artery infusion program.
Janczewski LM; Joung RH; Borhani AA; Lewandowski RJ; Velichko YS; Mulcahy MF; Mahalingam D; Law J; Bowman C; Keswani RN; Poylin VY; Bentrem DJ; Merkow RP
HPB (Oxford); 2024 May; 26(5):656-663. PubMed ID: 38383208
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma.
Yamaba S; Imai Y; Sugawara K; Uchida Y; Fuchigami A; Uchiya H; Nakayama N; Mochida S
PLoS One; 2024; 19(4):e0298770. PubMed ID: 38687817
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of dual checkpoint inhibitors in a patient with a mixed hepatocellular cholangiocarcinoma.
Sucre S; Bullock A; Peters ML
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38697678
[TBL] [Abstract][Full Text] [Related]
17. Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy for borderline resectable and unresectable colorectal liver metastases: phase II feasibility study.
Krul MF; Kok NFM; Osmani H; Buisman FE; Groot Koerkamp B; Grunhagen DJ; Verhoef C; Mostert B; Snaebjornsson P; Westerink B; Klompenhouwer EG; Donswijk ML; Ruers TJM; Douma JAJ; van Blijderveen N; Kingham TP; D'Angelica MI; Kemeny NE; Bolhuis K; Buffart TE; Kuhlmann KFD
Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38608150
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases.
Feng AW; Guo JH; Gao S; Kou FX; Liu SX; Liu P; Chen H; Wang XD; Xu HF; Cao G; Zhu X
Front Oncol; 2022; 12():913017. PubMed ID: 36212504
[TBL] [Abstract][Full Text] [Related]
19. Hepatic Artery Infusion Pump Combined With Systemic Chemotherapy for Patients With Liver Metastases From Breast Carcinoma.
Shi HB; Qiang WG; Zhu WL; Yuan Y; Wang JJ; Zhao JM; Hu WW
Technol Cancer Res Treat; 2021; 20():15330338211051552. PubMed ID: 34657511
[No Abstract] [Full Text] [Related]
20. Intraarterial Chemotherapy for Liver Metastases.
Connell LC; Kemeny NE
Surg Oncol Clin N Am; 2021 Jan; 30(1):143-158. PubMed ID: 33220802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
